Initiation, adherence to AIs low for older women with DCIS
4.7 (633) · $ 11.50 · In stock
(HealthDay)—For older women with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS), initiation of aromatase inhibitors (AIs) and adherence to treatment are low, according to a study published online Oct. 25 in Cancer.
PDF) Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews
PDF) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: A systematic review
Initiation, adherence to AIs low for older women with DCIS
Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic
Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer - Data Points Publication Series - NCBI Bookshelf
Cancers, Free Full-Text
Treatment coverage according to medication, age, and duration of treatment
Half of DCIS-treated women don't get ongoing imaging surveillance
Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer - Data Points Publication Series - NCBI Bookshelf
Adjuvant Hormonal Therapy Adherence in Breast Cancer - BCTT
Arthralgia in Breast Cancer Survivors: An Integrative Review of Endocrine Therapy
Cancers, Free Full-Text
Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer - Data Points Publication Series - NCBI Bookshelf
Adjuvant Hormonal Therapy Adherence in Breast Cancer - BCTT
